Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
After normalization of the steatosis-related circRNA by expression vector, analysis of miR-34a activity, peroxisome proliferator-activated receptor (PPAR)α level, and expression of downstream genes were carried out so as to reveal its impact on the miR-34a/PPARα regulatory system.
|
29391755 |
2018 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amelioration of hepatic steatosis is associated with modulation of gut microbiota and suppression of hepatic miR-34a in <i>Gynostemma pentaphylla</i> (Thunb.) Makino treated mice.
|
30555521 |
2018 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Activating AMPK<i>α</i> negatively regulates Egr1 to inhibit inflammatory cytokines in high glucose. miR-34a inhibition increases phosphorylated AMPK<i>α</i> through mediating SIRT1 to suppress the development of fatty liver.
|
29681936 |
2018 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings indicate a circRNA_0046367/miR-34a/PPAR<i>α</i> regulatory system underlying hepatic steatosis.
|
29018509 |
2017 |
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We found that hepatic miR-34a expression was upregulated in ethanol-fed mice and heavy drinkers with steatohepatitis compared with respective controls.
|
29128099 |
2017 |
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease.
|
26330104 |
2015 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we show that hepatocyte nuclear factor 4α (HNF4α), a liver-enriched nuclear hormone receptor, is markedly inhibited, whereas miR-34a is highly induced in patients with non-alcoholic steatohepatitis, diabetic mice and mice fed a high-fat diet. miR-34a is essential for HNF4α expression and regulates triglyceride accumulation in human and murine hepatocytes. miR-34a inhibits very low-density lipoprotein secretion and promotes liver steatosis and hypolipidemia in an HNF4α-dependent manner.
|
26100857 |
2015 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
p53 and its transcriptional target miRNA34a have been implicated in the pathogenesis of fatty liver.
|
23211317 |
2013 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
CTD_human |
The miR-34a/NAMPT axis presents a potential target for treating obesity- and aging-related diseases involving SIRT1 dysfunction like steatosis and type 2 diabetes.
|
23834033 |
2013 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
MicroRNA-34a (miR-34a) is the most highly elevated hepatic miR in obese mice and is also substantially elevated in patients who have steatosis, but its role in obesity and metabolic dysfunction remains unclear.
|
22988100 |
2012 |
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Again, miR-122 and miR-34a levels positively correlated with disease severity from simple steatosis to steatohepatitis.
|
21886843 |
2011 |
Fatty Liver
|
0.360 |
Biomarker
|
disease |
BEFREE |
Amelioration of hepatic steatosis is associated with modulation of gut microbiota and suppression of hepatic miR-34a in <i>Gynostemma pentaphylla</i> (Thunb.) Makino treated mice.
|
30555521 |
2018 |
Fatty Liver
|
0.360 |
Biomarker
|
disease |
BEFREE |
Dysregulation of circRNA_0046366/miR-34a/PPARα signaling may be a novel epigenetic mechanism underlying hepatocellular steatosis. circRNA_0046366 serves as a potential target for the treatment of hepatic steatosis.
|
29391755 |
2018 |
Fatty Liver
|
0.360 |
Biomarker
|
disease |
BEFREE |
Activating AMPK<i>α</i> negatively regulates Egr1 to inhibit inflammatory cytokines in high glucose. miR-34a inhibition increases phosphorylated AMPK<i>α</i> through mediating SIRT1 to suppress the development of fatty liver.
|
29681936 |
2018 |
Fatty Liver
|
0.360 |
Biomarker
|
disease |
BEFREE |
These findings indicate a circRNA_0046367/miR-34a/PPAR<i>α</i> regulatory system underlying hepatic steatosis.
|
29018509 |
2017 |
Fatty Liver
|
0.360 |
Biomarker
|
disease |
BEFREE |
Here we show that hepatocyte nuclear factor 4α (HNF4α), a liver-enriched nuclear hormone receptor, is markedly inhibited, whereas miR-34a is highly induced in patients with non-alcoholic steatohepatitis, diabetic mice and mice fed a high-fat diet. miR-34a is essential for HNF4α expression and regulates triglyceride accumulation in human and murine hepatocytes. miR-34a inhibits very low-density lipoprotein secretion and promotes liver steatosis and hypolipidemia in an HNF4α-dependent manner.
|
26100857 |
2015 |
Fatty Liver
|
0.360 |
Biomarker
|
disease |
CTD_human |
Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT.
|
23834033 |
2013 |
Fatty Liver
|
0.360 |
Biomarker
|
disease |
BEFREE |
p53 and its transcriptional target miRNA34a have been implicated in the pathogenesis of fatty liver.
|
23211317 |
2013 |
Obesity
|
0.350 |
Biomarker
|
disease |
BEFREE |
In addition, these genes are targeted by miRNAs related to schizophrenia (mir-34a) and obesity (mir-19b).
|
31447353 |
2019 |
Obesity
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
We identified four miRNAs overexpressed in obesity (miR-222, miR-142-3, miR-140-5p, and miR-143) and two miRNAs (miR-122 and miR-34a) overexpressed in children with obesity and nonalcoholic fatty liver disease (NAFLD) and/or insulin resistance.
|
31783635 |
2019 |
Obesity
|
0.350 |
Biomarker
|
disease |
BEFREE |
Epigenetic origin of the link between obesity and breast cancer (BC) is investigated in a cohort of Tunisian patients, focusing on polymorphism at germline level (miR-146a) and on expression in mammary tumors (miR-21, miR-146a, and miR-34a), according to body mass index (BMI) and clinico-pathologic features.
|
30303554 |
2019 |
Obesity
|
0.350 |
Biomarker
|
disease |
BEFREE |
Recent microRNA (miR) studies have revealed that aberrantly elevated miR-34a in obesity directly targets β-Klotho, the obligate coreceptor for both FGF19 and FGF21, and attenuates metabolic signaling of these hormones.
|
27125742 |
2016 |
Obesity
|
0.350 |
Biomarker
|
disease |
CTD_human |
Hepatic overexpression of miR-34a reduced NAMPT/NAD(+) levels, increased acetylation of the SIRT1 target transcriptional regulators, PGC-1α, SREBP-1c, FXR, and NF-κB, and resulted in obesity-mimetic outcomes.
|
23834033 |
2013 |
Obesity
|
0.350 |
Biomarker
|
disease |
BEFREE |
These results indicate that aberrantly elevated miR-34a in obesity attenuates hepatic FGF19 signaling by directly targeting βKL.
|
22988100 |
2012 |
Impaired glucose tolerance
|
0.310 |
Biomarker
|
phenotype |
BEFREE |
The molecular mechanism under the glucose intolerance responses which affects the growth performance and feed utilization is still confused. miR-34a was reported as a key regulator in the glucose metabolism, but how did the miR-34a exert its function in the metabolism of glucose/insulin in <i>M. amblycephala</i> was still unclear.
|
30115855 |
2018 |